Rinri Therapeutics is a private biotechnology company developing the world’s first regenerative cell therapies for hearing loss. The company’s pioneering technology seeks to reverse sensorineural hearing loss (SNHL), the leading form of deafness, through the repair and regeneration of the damaged cytoarchitecture of the inner ear. There are currently no pharmacological treatment options for SNHL patients.

Rinri was founded in Sheffield in 2018 by Professor Marcelo Rivolta – a globally recognised Professor of Sensory Stem Cell Biology. He has been based at the University of Sheffield in the UK since 2001 and has written over 40 papers on the subject, many of which have been published in peer-review journals. The Rivolta Laboratory, which he established at the University of Sheffield, is dedicated to studying the biology and behaviour of auditory stem cells, and to exploring their potential to regenerate the damaged inner ear.

Rinri Therapeutics is a private company backed by Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures, Pioneer Group, the University of Sheffield and the UK Future Fund.

Rinri currently employs 9 full time staff, but with extensive partnering and outsourcing has >40 people dedicated to different projects around the UK and Europe.